CD4 T cells in tumor immunity

Springer Seminars in Immunopathology

Volumn 27, Issue 1, 2005, Pages 37-48

  Gerloni, Mara ^a   Zanetti, Maurizio ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

CD4 T cells; MHC class II; Th Th cell cooperation; Tumor immunity

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; TUMOR ANTIGEN;

CELL INTERACTION; CELLULAR IMMUNITY; CYTOTOXICITY; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOREGULATION; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR RECOGNITION; NONHUMAN; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY;

ANIMALS; ANTIGENS, NEOPLASM; CD4-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE COOPERATION; NEOPLASMS;

EID: 21344438670     PISSN: 03444325     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00281-004-0193-z     Document Type: Review

References (82)

1. Burnet FM (1971) Immunological surveillance in neoplasia. Transplant Rev 7:3
2. Rammensee HG, Friede T, Stevanoviic S (1995) MHC ligands and peptide motifs: first listing. Immunogenetics 41:178
3. O'Garra A, Murphy K (1994) Role of cytokines in determining T-lymphocyte function. Curr Opin Immunol 6:458
4. Waldmann TA (2003) Immunotherapy: past, present and future. Nat Med 9:269
5. Kappler JW, Roehm N, Marrack P (1987) T cell tolerance by clonal elimination in the thymus. Cell 49:273
6. Cobbold SP, Adams E, Marshall SE, et al (1996) Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol Rev 149:5
7. Ochsenbein AF, Klenerman P, Karrer U, et al (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci USA 96:2233
8. Sercarz EE, Lehmann PV, Ametani A, et al (1993) Dominance and crypticity of T cell antigenic determinants. Annu Rev Immunol 11:729
9. Mitchison NA (1971) The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation. Eur J Immunol 1:18
10. Keene JA, Forman J (1982) Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J Exp Med 155:768
11. Swain SL, Bradley LM, Croft M, et al (1991) Helper T-cell subsets: phenotype, function and the role of lymphokines in regulating their development. Immunol Rev 123:115
12. Carter LL, Dutton RW (1996) Type 1 and type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol 8:336
13. + T lymphocytes. Nature 421:852
14. Shedlock DJ, Shen H (2003) Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science 300:337
15. Sun JC, Bevan MJ (2003) Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300:339
16. + T cells after acute infection. Nat Immunol 5:927
17. Langlade-Demoyen P, Garcia-Pons F, Castiglioni P, et al (2003) Role of T cell help and endoplasmic reticulum targeting in protective CTL response against influenza virus. Eur J Immunol 33:720
18. Ossendorp F, Mengede E, Camps M, et al (1998) Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 187:693
19. - lymphocytes. J Exp Med 154:952
20. - T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity. J Immunol 133:1671
21. + T cell-dependent tumor rejection. J Exp Med 174:1291
22. + T cells and immunosurveillance of B-cell tumors. Proc Natl Acad Sci USA 91:5700
23. Hung K, Hayashi R, Lafond-Walker A, et al (1998) The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188:2357
24. Heath WR, Carbone FR (1999) Cytotoxic T lymphocyte activation by cross-priming. Curr Opin Immunol 11:314
25. Pieper R, Christian RE, Gonzales MI, et al (1999) Biochemical identification of a mutated human melanoma antigen recognized by CD4(+) T cells. J Exp Med 189:757
26. Wang RF, Wang X, Rosenberg SA (1999) Identification of a novel major histocompatibility complex class II-restricted tumor antigen resulting from a chromosomal rearrangement recognized by CD4(+) T cells. J Exp Med 189:1659
27. Wang RF, Wang X, Atwood AC, et al (1999) Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284:1351
28. Greenberg PD (1991) Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv Immunol 49:281
29. Dighe AS, Richards E, Old LJ, et al (1994) Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors. Immunity 1:447
30. Williamson BD, Carswell EA, Rubin BY, et al (1983) Human tumor necrosis factor produced by human B-cell lines: synergistic cytotoxic interaction with human interferon. Proc Natl Acad Sci USA 80:5397
31. Fransen L, Van der Heyden J, Ruysschaert R, et al (1986) Recombinant tumor necrosis factor: its effect and its synergism with interferon-gamma on a variety of normal and transformed human cell lines. Eur J Cancer Clin Oncol 22:419
32. Coughlin CM, Salhany KE, Gee MS, et al (1998) Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis. Immunity 9:25
33. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12:677
34. Gerloni M, Xiong S, Mukerjee S, et al (2000) Functional cooperation between Th cell determinants. Proc Natl Acad Sci USA 97:13269
35. Hilkens J, Buijs F, Hilgers J, et al (1984) Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 34:197
36. Lloyd KO, Burchell J, Kudryashov V, et al (1996) Comparison of O-linked carbohydrate chains in MUC-1 mucin from normal breast epithelial cell lines and breast carcinoma cell lines. Demonstration of simpler and fewer glycan chains in tumor cells. J Biol Chem 271:33325
37. Gerloni M, Miner KT, Xiong S, et al (1999) Activation of CD4 T cells by somatic transgenesis induces generalized immunity of uncommitted T cells and immunologic memory. J Immunol 162:3782
38. Pecher G, Finn OJ (1996) Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc Natl Acad Sci USA 93:1699
39. Gong J, Chen D, Kashiwaba M, et al (1998) Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc Natl Acad Sci USA 95:6279
40. Soares MM, Mehta V, Finn OJ (2001) Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 166:6555
41. + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J Immunol 161:5500
42. Bretscher P, Cohn M (1970) A theory of self-nonself discrimination. Science 169:1042
43. Gershon RK (1975) A disquisition on suppressor T cells. Transplant Rev 26:170
44. + suppressor T cells. Immunol Rev 182:58
45. Roncarolo MG, Bacchetta R, Bordignon C, et al (2001) Type 1 T regulatory cells. Immunol Rev 182:68
46. + T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 172:4676
47. Cantor H (2004) Reviving suppression? Nat Immunol 5:347
48. + T cells in murine experimental allergic encephalomyelitis. Science 256:1213
49. North RJ (1982) Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155:1063
50. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211
51. Onizuka S, Tawara I, Shimizu J, et al (1999) Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res 59:3128
52. Daniels GA, Sanchez-Perez L, Diaz RM, et al (2004) A simple method to cure established tumors by inflammatory killing of normal cells. Nat Biotechnol 22:1125
53. Sutmuller RP, Duivenvoorde LM van, Elsas A van, et al (2001) Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 194:823
54. + regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336
55. + regulatory T cells that express toll-like receptors. J Exp Med 197:397
56. + suppressor lymphocytes in the circulation of patients immunized against melanoma antigens. J Immunother 26:85
57. high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J Immunol 173:1444
58. Curiel TJ, Coukos G, Zou L, et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942
59. Padua RA, Larghero J, Robin M, et al (2003) PML-RARA-targeted DNA vaccine induces protective immunity in a mouse model of leukemia. Nat Med 9:1413
60. Lehmann PV, Forsthuber T, Miller A, et al (1992) Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature 358:155
61. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20:107
62. + T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase. Cancer Res 58:296
63. Kobayashi H, Kokubo T, Takahashi M, et al (1998) Tyrosinase epitope recognized by an HLA-DR-restricted T-cell line from a Vogt-Koyanagi-Harada disease patient. Immunogenetics 47:398
64. Touloukian CE, Leitner WW, Schnur RE, et al (2003) Normal tissue depresses while tumor tissue enhances human T cell responses in vivo to a novel self/tumor melanoma antigen, OA1. J Immunol 170:1579
65. Zarour HM, Kirkwood JM, Kierstead LS, et al (2000) Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. Proc Natl Acad Sci USA 97:400
66. Li K, Adibzadeh M, Halder T, et al (1998) Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells. Cancer Immunol Immunother 47:32
67. Touloukian CE, Leitner WW, Topalian SL, et al (2000) Identification of a MHC class II-restricted human gp100 epitope using DR4-IE transgenic mice. J Immunol 164:3535
68. Chaux P, Vantomme V, Stroobant V, et al (1999) Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes. J Exp Med 189:767
69. Manici S, Sturniolo T, Imro MA, et al (1999) Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11. J Exp Med 189:871
70. Campi G, Crosti M, Consogno G, et al (2003) CD4(+) T cells from healthy subjects and colon cancer patients recognize a carcinoembryonic antigen-specific immunodominant epitope. Cancer Res 63:8481
71. + T cell epitopes from NY-ESO-1 presented by HLA-DR molecules. J Immunol 165:1153
72. + T cells. Cancer Res 60:4946
73. Zeng G, Wang X, Robbins PF, et al (2001) CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci USA 98:3964
74. + Th1/Th2 lymphocytes. J Immunol 172:5095
75. Maccalli C, Li YF, El-Gamil M, et al (2003) Identification of a colorectal tumor-associated antigen (COA-1) recognized by CD4(+) T lymphocytes. Cancer Res 63:6735
76. + T cells. Cancer Res 63:6506
77. Disis ML, Schiffman K, Gooley TA, et al (2000) Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. Clin Cancer Res 6:1347
78. + T cells. Cancer Res 63:3675
79. + T cells. Cancer Res 58:5066
80. Schroers R, Shen L, Rollins L, et al (2003) Human telomerase reverse transcriptase-specific T-helper responses induced by promiscuous major histocompatibility complex class II-restricted epitopes. Clin Cancer Res 9:4743
81. + T-cell immunity against early antigens E2 and E6. Cancer Res 64:5449
82. Kruger S, Schroers R, Rooney CM, et al (2003) Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1. J Immunother 26:212